Hyaluronidase-zzxf/pertuzumab/trastuzumab is an SC injection that contains a fixed-dose combination of trastuzumab and pertuzumab, which has been approved for treating patients with HER2-positive breast cancer (69). This evidence concerns the gene ERBB2 and breast cancer.